Chapters

Transcript

Video

Looking forward, what types of cancer do you think might prove to be amenable to nemvaleukin therapy?


Created by

CMEducation Resources | iQ&A Cytokine Immunotherapy Intelligence Zone

Presenter

Michael Lotze, MD, PhD

Michael Lotze, MD, PhD

Professor of Surgery, Immunology, and BioengineeringUniversity of Pittsburgh Cancer InstituteUniversity of Pittsburgh School of MedicineAssistant Vice Chancellor, Sponsored Training GrantsUniversity of Pittsburgh Schools of the Health SciencesPittsburgh, PA